An Association Between Liraglutide Treatment and Reduction in Excessive Daytime Sleepiness in Obese Subjects with Type 2 Diabetes

A study was conducted to see whether liraglutide helped with improving excessive daytime sleepiness for those with Type II diabetes who were also obese. This included 158 obese adults with a body mass of over 30kg/m2 and Type II diabetes who had begun liraglutide therapy at the start of the study. A significant amount of data was collected, including data from the Epworth Sleeping Scale (ESS), anthropometric parameters, glucose-control, and metabolic parameters. This data was collected at baseline and at both one month and three months after baseline.

The results showed major reductions in ESS score with the study participants at both months 1 and 3 (-1.3±2 p <0.001 and -1.5 ± 3.0 p<-.001, respectively). Significant reductions were also seen after 3 months in body weight, BMI, waist and neck circumferences, HbA1c, mean blood glucose, fasting blood glucose, triglycerides, and total cholesterol levels.

Overall, 3 months of liraglutide treatment proved effective in reducing excessive daytime sleepiness in obese participants with Type II diabetes. More research is required to see if liraglutide could improve other abnormal sleep pattern disorders and obstructive sleep aponea. I am wondering if liraglutide does one day prove to be effective in improving these disorders, would it be able to be indicated for patients without diabetes or obesity but with sleep disorders?

BMC Endocr Disord. 2015 Dec 4;15:78

1 thought on “An Association Between Liraglutide Treatment and Reduction in Excessive Daytime Sleepiness in Obese Subjects with Type 2 Diabetes”

  1. One thing that I find interesting about the results of this article is that Liraglutide seemed to help with weight loss. So not only does it help with sleep and blood glucose levels, but also could possibly see positive effects as a weight loss drug. I know many people with diabetes, and it is very hard for them to lose weight, so I am curious as to how much change was seen in weight, BMI, and circumferences of respective areas. I think it is great when a drug can treat multiple conditions at once because it reduces the number of medications a person may need to take. Especially if the different conditions are all underlying effects of one disease state. For example, if a person has diabetes, they typically have a greater chance of being obese. When a person is obese, they may find themselves more tired than usual, and therefore, may sleep more. If a medications like Liraglutide can treat the source of the problem, the other symptoms can then be reduced without the use of other medications or therapies. It reminds me of the analogy from Anatomy this week: it is important to see the whole forest and not just one particular tree that may have a smaller issue.

Leave a Reply